CPIX - Company ID 0001087294
The table below shows CUMBERLAND PHARMACEUTICALS INC's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $44.52M | $37.87M | $39.55M | $42.01M | $35.99M | $37.44M |
| Cost of revenue | $6.67M | $6.59M | $6.07M | $9.12M | $8.81M | $8.65M |
| Gross profit | - | - | - | - | - | - |
| R&D | $5.57M | $4.82M | $5.83M | $6.69M | $5.68M | $5.77M |
| SG&A |
CUMBERLAND PHARMACEUTICALS INC reported annual revenue of $44.52M for fiscal year 2025. That is up 17.6% from $37.87M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $33.03M (FY 2016) to $44.52M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $11.95M |
| $11.13M |
| $10.65M |
| $10.18M |
| $9.78M |
| $10.20M |
| Operating income | -$2.79M | -$6.43M | -$9.55M | -$5.70M | -$7.68M | -$6.38M |
| Income tax | $40.26K | -$22.67K | $45.77K | $68.85K | $34.89K | $55.90K |
| Net income | -$2.84M | -$6.48M | -$6.28M | -$5.57M | -$3.51M | -$3.34M |
| EPS (diluted) | -$0.19 | -$0.46 | -$0.44 | -$0.38 | -$0.24 | -$0.22 |